Grace Therapeutics, Inc. Current Assets
Grace Therapeutics, Inc. (GRCE) had Current Assets of $14.33 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-13
- 2026-06-30: Assets, Current $14.33M.
- 2026-03-31: Assets, Current $17.38M.
- 2025-12-31: Assets, Current $19.21M.
- 2025-09-30: Assets, Current $17.30M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $14.33M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $17.38M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $19.21M 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $17.30M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $20.52M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $22.71M 10-K · filed 2026-06-18 | |
| 2024-12-31 | $11.94M 10-Q · filed 2025-02-13 | |
| 2024-09-30 | $16.06M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $20.43M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $24.01M 10-K · filed 2025-06-23 | |
| 2023-12-31 | $26.88M 10-Q · filed 2024-02-12 | |
| 2023-09-30 | $28.89M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $23.61M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $29.29M 10-K · filed 2024-06-21 | |
| 2022-12-31 | $33.43M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | $37.51M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $41.25M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $45.28M 10-K · filed 2023-06-23 | $45.53M 10-K · filed 2022-06-21 |
| 2021-12-31 | $49.00M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $54.55M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $60.39M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $62.37M 10-K · filed 2022-06-21 | |
| 2020-12-31 | $30.20M 10-Q · filed 2021-02-09 | |
| 2020-09-30 | $13.71M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $13.96M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $18.46M 10-K · filed 2021-06-22 | $16.08M 10-K · filed 2020-06-29 |
| 2019-03-31 | $27.97M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |